supp.fit

Niacin, Coenzyme Q10 and Riboflavin: study protocols

7 study groups took Niacin together with Coenzyme Q10 and Riboflavin. These are the doses the studies gave. They are not a recommendation.

Niacin: what the research found →

Dose per serving from research: Niacin

7 study groups in 4 studies say how much Niacin participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 25 mg to 50 mg, 100% of 7 study groups.

Daily doseStudy groups
25 mg to 50 mg
7

Dose per serving from research: Coenzyme Q10

7 study groups in 4 studies say how much Coenzyme Q10 participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 50 mg to 100 mg, 100% of 7 study groups.

Daily doseStudy groups
50 mg to 100 mg
7

Dose per serving from research: Riboflavin

7 study groups in 4 studies say how much Riboflavin participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 5 mg to 10 mg, 100% of 7 study groups.

Daily doseStudy groups
5 mg to 10 mg
7

Commonly used together

None of these 7 study groups took Niacin, Coenzyme Q10 and Riboflavin with anything else.

7 study groups

Study
Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy
2007 · Group IV (CoRN for 45 days) · Breast cancer patients undergoing tamoxifen therapy; age and sex not specified
50 mg100 mg10 mg45 days—
Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy
2007 · Group V (CoRN for 90 days) · Breast cancer patients undergoing tamoxifen therapy; age and sex not specified
50 mg100 mg10 mg90 days—
Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin
2007 · Group IV (CoRN for 45 days) · Breast cancer patients treated with tamoxifen
50 mg100 mg10 mg45 days—
Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin
2007 · Group V (CoRN for 90 days) · Breast cancer patients treated with tamoxifen
50 mg100 mg10 mg90 days—
Co-enzyme Q10, riboflavin and niacin supplementation on alteration of DNA repair enzyme and DNA methylation in breast cancer patients undergoing tamoxifen therapy
2008 · CoRN supplement plus tamoxifen · Breast cancer patients undergoing tamoxifen therapy
50 mg100 mg10 mg——
Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy
2008 · Group IV (CoRN for 45 days) · Breast cancer patients receiving tamoxifen therapy for more than 1 year; age not reported
50 mg100 mg10 mg45 days—
Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy
2008 · Group V (CoRN for 90 days) · Breast cancer patients receiving tamoxifen therapy for more than 1 year; age not reported
50 mg100 mg10 mg90 days—
Niacin, Coenzyme Q10 and Riboflavin: study protocols | supp.fit